This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Vernix caseosa, or simply vernix, is the waxy white substance found coating the skin of newborn human babies. It is produced by dedicated cells and is thought to have some protective roles during fetal development and for a few hours after birth.
=== Methylene blue value of fine aggregate === The methylene blue value is defined as the number of milliliters of standard methylene blue solution decolorized 0.1 g of activated carbon (dry basis). Methylene blue value reflects the amount of clay minerals in aggregate samples. In materials science, methylene blue solution is successively added to fine aggregate which is being agitated in water. The presence of free dye solution can be checked with a stain test on a filter paper.
== Functions == Some fusion proteins combine whole peptides and therefore contain all functional domains of the original proteins. However, other fusion proteins, especially those that occur naturally, combine only portions of coding sequences and therefore do not maintain the original functions of the parental genes that formed them. Many whole gene fusions are fully functional and can still act to replace the original peptides. Some, however, experience interactions between the two proteins that can modify their functions. Beyond these effects, some gene fusions may cause regulatory changes that alter when and where these genes act. For partial gene fusions, the shuffling of different active sites and binding domains have the potential to result in new proteins with novel functions.
=== Hydraulics === Liquid is the primary component of hydraulic systems, which take advantage of Pascal's law to provide fluid power. Devices such as pumps and waterwheels have been used to change liquid motion into mechanical work since ancient times. Oils are forced through hydraulic pumps, which transmit this force to hydraulic cylinders. Hydraulics can be found in many applications, such as automotive brakes and transmissions, heavy equipment, and airplane control systems. Various hydraulic presses are used extensively in repair and manufacturing, for lifting, pressing, clamping and forming.
Sources: en.wikipedia.org
Quantitative proteomics is an analytical chemistry technique for determining the amount of various proteins, including cofactors, in a sample. The methods for protein identification and separation are identical to those used in general qualitative proteomics, but include quantification as an additional dimension. Rather than just providing lists of proteins identified in a certain sample, quantitative proteomics yields information about the physiological differences between two biological samples. For example, this approach can be used to compare samples from healthy and diseased patients. Quantitative proteomics is mainly performed by two-dimensional gel electrophoresis (2-DE), preparative native PAGE, or mass spectrometry (MS). However, a recent developed method of quantitative dot blot (QDB) analysis is able to measure both the absolute and relative quantity of individual proteins in the sample in high throughput format, thus, open a new direction for proteomic research. In contrast to 2-DE, which requires MS for the downstream protein identification, MS technology can identify and quantify the structural changes and physiological functions.
In March 2018, Russian president Vladimir Putin told journalist Megyn Kelly in an interview: "My point of view is that the individuals that have said that a new Cold War has started are not analysts. They do propaganda." Michael Kofman, a senior research scientist at the CNA Corporation and a fellow at the Wilson Center's Kennan Institute said that the causes and character of the new conflict between Russia and the West over Ukraine and Georgia are different from the Cold War. He said the Cold War "was a battle for global dominance between two universalist ideologies" while this new conflict for Russia "is about its survival as a power in the international order, and also about holding on to the remnants of the Russian empire". Lyle Goldstein, a research professor at the US Naval War College said that the situations in Georgia and Ukraine "seemed to offer the requisite storyline for new Cold War" between Russia and the West. Also in March 2018, Harvard University professors Stephen Walt, and then Odd Arne Westad, criticised the application of the term to increasing tensions between Russia and the West as "misleading", "distract[ing]", and too simplistic to describe the more complicated contemporary international politics. In October 2018, Russian military analyst Pavel Felgenhauer told Deutsche Welle that "we have a new Cold War, so the treaties that ended the previous one are irrelevant because they correspond to a totally different world situation", referring to the Intermediate-Range Nuclear Forces (INF) Treaty and others.
The jury really is still out on these bodies, whether they were aristocrats, priests, criminals, outsiders, whether they went willingly to their deaths or whether they were executed – but Lindow was a very remote place in those days, an unlikely place for an ambush or a murder According to Anne Ross, an archaeologist and scholar of Celtic history, and Don Robins, a chemist at the University of London, Lindow Man was likely a sacrifice victim of extraordinary importance. They identified his stomach contents as including the undigested remains of a partially burned barley griddle cake of a kind used by the ancient Celts to select victims for sacrifice. Such cakes were torn into fragments and placed in a sack, after which all candidates for sacrifice would withdraw a piece, with the one withdrawing the burnt piece being the one who would be sacrificed. They argued that Lindow Man was likely a high-ranking Druid who was sacrificed in a last-ditch effort to call upon the aid of three Celtic gods to stop a Roman offensive against the Celts in AD 60.
A study using plasma proteomics aging clocks suggests nearly 20% of the population may show strongly accelerated age in one of 11 major organs, which it links to higher mortality risk. Biological and biotechnical rejuvenation-related results In January, a team led by David Sinclair shows in a 13-year-long international study how DNA breaks or epigenetic damage are a major driver of epigenetic change, and how the loss of epigenetic information is a cause of aging in mammals. It concluded that the loss of epigenetic information can drive aging independently of changes to the genetic code, suggesting that epigenetic change is a primary driver of aging in mammals. Using a treatment based on Yamanaka factors, they demonstrate an ability to drive aging in both the forward and reverse directions in mice. In a preprint, another team of researchers of the biotechnology company Rejuvenate Bio also reports the use of Yamanaka-reprogramming to modestly extend the lives of elderly mice. However, if it was also applicable to humans, risks may include the formation of cancer. In July, the David Sinclair team at Harvard Medical School release a study that claims to have discovered the first known chemical approach to reprogram cells to a younger state by delivering the Yamanaka factors directly, whereas previously this had only been achievable via gene therapy. A study indicates factors contributing to the longevity of long-living organisms can be transferred between species, particularly from naked mole-rats to mice.
=== Fencing === The sport reached its peak during the 2020 and 2024 Olympic Games. Cheung Ka-long became a national icon by winning back-to-back gold medals in men's individual foil, while Vivian Kong secured gold in women's individual épée in Paris 2024.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.